Futura Medical PLC
LSE:FUM

Watchlist Manager
Futura Medical PLC Logo
Futura Medical PLC
LSE:FUM
Watchlist
Price: 32 GBX 0.16%
Market Cap: 97.2m GBX
Have any thoughts about
Futura Medical PLC?
Write Note

Futura Medical PLC
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Futura Medical PLC
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Futura Medical PLC
LSE:FUM
Total Liabilities
ÂŁ2.2m
CAGR 3-Years
44%
CAGR 5-Years
-9%
CAGR 10-Years
17%
GlaxoSmithKline PLC
LSE:GSK
Total Liabilities
ÂŁ43.7B
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Total Liabilities
$64.8B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
Total Liabilities
$251.3m
CAGR 3-Years
96%
CAGR 5-Years
70%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Total Liabilities
$2.6B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
11%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Liabilities
ÂŁ814.2m
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
13%
No Stocks Found

Futura Medical PLC
Glance View

Market Cap
95.7m GBX
Industry
Pharmaceuticals

Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

FUM Intrinsic Value
15.77 GBX
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Futura Medical PLC's Total Liabilities?
Total Liabilities
2.2m GBP

Based on the financial report for Jun 30, 2024, Futura Medical PLC's Total Liabilities amounts to 2.2m GBP.

What is Futura Medical PLC's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
17%

Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Futura Medical PLC have been 44% over the past three years , -9% over the past five years , and 17% over the past ten years .

Back to Top